Brief: Arbutus & Barinthus Bio Announce New Data From The IM-PROVE II Trial
15/11/2024 17:19
Nov 15 (Reuters) - Arbutus Biopharma Corp ABUS.O :
* ARBUTUS AND BARINTHUS BIO ANNOUNCE NEW DATA FROM THE
IM-PROVE II
TRIAL SHOWING THAT THE ADDITION OF NIVOLUMAB INCREASED RATES OF
HBSAG LOSS IN PEOPLE WITH CHRONIC HEPATITIS B
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Arbutus Biopharma
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Arbutus rises after FDA lifts clinical hold for experimental hepatitis B drug
Brief: Arbutus Announces Final Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
Brief: Arbutus Announces Preliminary Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare